Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-916P refers to a pseudogene related to U6 small nuclear RNA (snRNA), which is a crucial noncoding RNA component of the spliceosome involved in mRNA splicing[4][5]. However, as a pseudogene, RNU6-916P is generally considered nonfunctional and is presumed not to produce an active RNA product, nor to participate in spliceosomal activity or regulatory pathways. It has no established biological or therapeutic role, no associated drugs or mechanisms of action, and is not reported to serve as a biomarker or disease-associated gene. U6 snRNA pseudogenes are common in vertebrate genomes and are likely evolutionary remnants rather than active genetic elements[2][4][5]. There is nothing to suggest that RNU6-916P is a therapeutically actionable target, and its inclusion as a target would generally be considered incorrect, as it lacks the functional attributes of receptors, enzymes, ion channels, or similar entities[2][4]. If you are interested in the functional canonical U6 small nuclear RNA, see entries for "RNA, U6 small nuclear 1 (RNU6-1)" or similar[6][4][5].
No mechanism; not a functional target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 916, pseudogene (RNU6-916P).